The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
Ruxolitinib is increasingly being utilized for the treatment of myelofibrosis and polycythemia vera, but the potential for hepatic toxicity is poorly understood. We performed a retrospective review of hepatic damage occurring in patients with myeloproliferative neoplasms receiving ruxolitinib. Relev...
Saved in:
Main Authors: | Douglas Tremblay, Juan Putra, Alexander Vogel, Adam Winters, Ronald Hoffman, Thomas D. Schiano, Maria Isabel Fiel, John O. Mascarenhas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/3294046 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Hematopoietic Niche in Myeloproliferative Neoplasms
by: Annette H. Schmitt-Graeff, et al.
Published: (2015-01-01) -
Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
by: Patrycja Zielinska, et al.
Published: (2014-01-01) -
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
by: Sylvie Hermouet, et al.
Published: (2015-01-01) -
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
by: Vladan P. Čokić, et al.
Published: (2015-01-01) -
Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms
by: Raunak Rao, et al.
Published: (2020-01-01)